Hemoglobin A1c Monitoring - Global Market Trends

Published by	BizAcumen, Inc.
Published	April, 2010	Product code	104271
Content info	Pages: 192
Price	US $ 2995 PDF by E-mail (Single user license) US $ 8985 PDF By E-mail (Global License to Company and its Fully-owned Subsidiaries)

Introduction
Press Release
Related Reports

Hemoglobin A1c Monitoring - Global Market Trends published by BizAcumen, Inc. in April, 2010. This report consists of Pages: 192 and the price starts from US $ 2995.

Introduction

Abstract

The seriousness of affliction and the need for effective therapy to manage diabetes has led to the emergence of a significant market for monitoring the treatment efficiency of the disease. Other factors such as greater glucose control, product innovations that help improve compliance or convenience comprise other growth drivers in hemoglobin A1C monitoring market.

Diabetes patients (Type I) who regularly monitor their HbA1c (hemoglobin A1C) levels attain tight glucose control, thus considerably reducing their vulnerability to a cardiovascular disease. High blood sugar level for a longer period of time could result to increase in risk of heart disease or stroke. An HBA1C level more that 4.6 indicate the person is at increased risk for heart attack. The ADA (American Diabetes Association), recommends an HbA1c test every 3 to 6 months for monitoring the levels of blood sugar in insulin-administered patients, patients with high blood glucose levels and patients with a change of therapy.

These and other market data and trends are presented in "Hemoglobin A1c Monitoring: Global Market Trends" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

1. METHODOLOGY

Study Reliability and Reporting Limitations
Disclaimers
Quantitative Techniques & Reporting Level

2. MARKET OVERVIEW

Diabetes Monitoring Market
Higher Levels of Glycosylated Hemoglobin Increases the Risk of Death
Regular HbA1c Test Keeps Heart Risk at Bay
- Home Monitoring

3. PRODUCT FACTS

HbA1c Laboratory Testing
HbA1c Point of Care Testing & Self- Monitoring

4. TECHNOLOGICAL DEVELOPMENTS

New Noninvasive Monitoring and Testing Devices
HGI as a Statistical Predictor of Nephropathy and Retinopathy
Micro-Optical Detection Method Technology - Metrika

5. REGULATORY ENVIRONMENT

Animas Obtains FDA Approval for OneTouch Glucose Management System
ARKRAY USA Obtains FDA Approval for GLUCOCARD
Bayer' s Breeze Blood Glucose Monitoring System Receives Commendation
Trinity Biotech Obtains FDA Approval for Point of Care HbA1c Test
MedApps Receives FDA Clearance for OTC Use of D-PAL Remote System
DexCom Receives FDA Approval for STS-7 System
Diazyme' s Direct Enzymatic HbA1c Assay Kit Receives FDA Clearance
Trinity Biotech Receives FDA Approval for TRIstat HbA1c Test

6. CORPORATE DEVELOPMENTS

Roche Inks Marketing Agreement with Mankind Pharma
Nicholas Piramal Forms Joint Venture with Arkray
Quotient Diagnostics to Commence Production of Quo-Test System
Pelikan and Eli Lilly Sign Co-Promotion Agreement
Quantimetrix Develops GlycoHemosure
Olympus Life Science Europa Unveils HbA1c assay
Siemens Healthcare Introduces DCA Vantage™ Analyser
Sysmex America and Bio-Rad Sign Long-term Distribution Agreement
Medtronic Enters in to Alliance with Bayer HealthCare
Inverness Snaps Up Cholestech
IQ Micro to Complete Lifecare Acquisition
Bio-Rad Introduces The in2it Analyzer
Abbott Diabetes Launches FreeStyle Lite™ Blood Glucose Meter
Bayer Introduces BREEZE®2 and CONTOUR® Blood Glucose Meters
ARKRAY Introduces PocketChem™EZ Blood Glucose Monitoring System
Abbott Rolls Out New Blood Glucose Monitoring Devices
Axis-Shield UK Introduces Afinion™
Medtronic Plans Launch of Online Testing Kit for Diabetes
Nova Biomedical Launches Nova Max™ Blood Glucose Monitoring System
Medtronic Announces Launch of New Continuous Glucose Monitoring System
LifeScan Offers Meter Upgrade for OneTouch® Blood Glucose Monitoring Systems

7. MAJOR PLAYERS

Abbott Laboratories (USA)
Axis-Shield (UK)
Bayer Healthcare Diabetes Care (USA)
Beckman Coulter, Inc. (USA)
Bio-Rad Laboratories Inc (USA)
Biosafe Laboratories Inc (USA)
Diabetes Technologies Inc (USA)
Flexsite Diagnostics Inc (USA)
Primus Diagnostics (USA)
Roche Diagnostics (Switzerland)
Tosoh Bioscience, Inc (USA)

8. GLOBAL MARKET ANALYTICS

9. THE UNITED STATES

An Insight
Market Highlights
Challenges in the HbA1c Monitoring Market in the US
Market Trends & Issues
- Impact of Pricing and Innovation
- HbA1c Monitoring Vs Blood Glucose Monitoring
- Impact Of Diabetes Education Campaigns On HbA1c Monitors Usage
- Impact of Sedentary Lifestyle
- Reimbursements from Managed Care Organizations
- The Diabetes A1c Initiative™

10. EUROPE

11. REST OF WORLD

Press Release

Hemoglobin A1c Monitoring Represents Significant Global Market for Diabetes Management

April 13th, 2010

Global Information, Inc. would like to present a new market research report, "Hemoglobin A1c Monitoring - Global Market Trends" by BizAcumen, Inc..

According to BizAcumen, Inc., "The seriousness of affliction and the need for effective therapy to manage diabetes has led to the emergence of a significant market for monitoring the treatment efficiency of the disease." The hemoglobin A1C monitoring market is driven by several factors, which includes greater glucose control for diabetic patients and convenient monitoring. Diabetes Type I patients who regularly monitor their HbA1c (hemoglobin A1C) levels attain tight glucose control, which considerably reduces their vulnerability to cardiovascular diseases. The American Diabetes Association (ADA) recommends a hemoglobin A1c test every 3 to 6 months for monitoring the levels of blood sugar in patients that take insulin, patients with high blood glucose levels, and patients undergoing therapy changes.